# Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

> **NCT07014280** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Kasr El Aini Hospital** · enrollment: 28 (actual)

## Conditions studied

- Keloids

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Triamcinolone Acetonide

## Key facts

- **NCT ID:** NCT07014280
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014280, "Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07014280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*